Keith T. Flaherty

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile

0.580Author DataRank

Indexed papers

8in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 8 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Papers

Driven by 85 papers — median percentile 0. Top paper: “Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity”.

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Science(2020)10.1126/science.abd4250

N/A

14.5DataRank · unranked

769 citations

Eric Fujimura, Tomasz Kula, Richard T. Timms, I‐Hsiu Lee, Yumei Leng +95 more

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

The Lancet Oncology(2021)10.1016/s1470-2045(20)30726-9

N/A

4.9DataRank · unranked

94 citations

Jennifer Wiggins, Broderick C. Corless, Georgina V. Long, Keith T. Flaherty, Dirk Schadendorf +12 more

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Journal of Clinical Oncology(2020)10.1200/jco.19.02630

N/A

4.7DataRank · unranked

179 citations

Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell +17 more

Targeting TBK1 to overcome resistance to cancer immunotherapy

Nature(2023)10.1038/s41586-023-05704-6

N/A

4.0DataRank · unranked

171 citations

Or‐Yam Revach, Seth Anderson, Emily Kessler, Clara Wolfe, Anne Jenney +54 more

Evolution of delayed resistance to immunotherapy in a melanoma responder

Nature Medicine(2021)10.1038/s41591-021-01331-8

N/A

3.6DataRank · unranked

137 citations

Jia‐Ren Lin, Emily Robitschek, Gyulnara G. Kasumova, Alex Heyde, Alvin Shi +35 more

Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome

Science Advances(2020)10.1126/sciadv.abb3461

N/A

2.0DataRank · unranked

60 citations

Gyulnara G. Kasumova, William A. Michaud, Jessica Cintolo-Gonzalez, Marta Díaz-Martínez, Jacqueline Ohmura +13 more

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

Science(2016)10.1126/science.aad0501

N/A

1.3DataRank · unranked

5121 citations

Benjamin Izar, Sanjay M. Prakadan, Marc H. Wadsworth, Daniel Treacy, John J. Trombetta +39 more

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Nature Medicine(2019)10.1038/s41591-019-0654-5

N/A

1.0DataRank · unranked

829 citations

Bastian Schilling, Derek Liu, Antje Sucker, Elisabeth Livingstone, Livnat Jerby-Arnon +34 more

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma

Cell Reports Medicine(2022)10.1016/j.xcrm.2021.100500

N/A

0.972DataRank · unranked

35 citations

Moshe Sade-Feldman, Jaegil Kim, Chip Stewart, Anna Gonye, Arvind Ravi +34 more

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

JCO Precision Oncology(2023)10.1200/po.22.00421

N/A

0.656DataRank · unranked

16 citations

Yael Flamand, Melissa Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong +19 more

A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152)

Cancer(2021)10.1002/cncr.34063

N/A

0.616DataRank · unranked

15 citations

Ju‐Whei Lee, Jill B. Gaieski, Shuli Li, Ilana F. Gareen, Keith T. Flaherty +15 more

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Nature Medicine(2020)10.1038/s41591-020-0975-4

N/A

0.564DataRank · unranked

12 citations

Bastian Schilling, Derek Liu, Antje Sucker, Elisabeth Livingstone, Livnat Jerby-Arnon +34 more

TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids

Cancer Immunology Research(2025)10.1158/2326-6066.cir-23-1011

N/A

0.530DataRank · unranked

15 citations

Luke Maggs, Apekshya Panda, Samuel J. Wright, Angelina M. Cicerchia, Anne Jenney +23 more

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

JCO Precision Oncology(2024)10.1200/po.23.00407

Top 40%

0.476DataRank

Top 40%10 citations

Alain C. Mita, Zihan Wei, Heather H. Cheng, Edith P. Mitchell, John J. Wright +16 more

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2 -Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0633

N/A

0.414DataRank · unranked

9 citations

Victoria Wang, Jaime B. Hyman, Petros Grivas, Edith P. Mitchell, John Wright +17 more

Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102210

N/A

0.382DataRank · unranked

9 citations

Angelina M. Cicerchia, Ofir Shorer, Claire A. Palin, Boryana Petrova, Seth Anderson +50 more

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.12.579184

N/A

0.290DataRank · unranked

5 citations

Angelina M. Cicerchia, Ofir Shorer, Boryana Petrova, Seth Anderson, Joshua Park +48 more

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U

JCO Precision Oncology(2024)10.1200/po.24.00327

N/A

0.260DataRank · unranked

4 citations

Opeyemi A. Jegede, David M. Jackman, James A. Zwiebel, Robert J. Gray, Victoria Wang +17 more

Plasma-derived exosomal analysis and deconvolution enables prediction and tracking of melanoma checkpoint blockade response

bioRxiv (Cold Spring Harbor Laboratory)(2019)10.1101/809699

N/A

0.219DataRank · unranked

2 citations

Gyulnara G. Kasumova, William A. Michaud, Jessica Cintolo-Gonzales, Marta Díaz Martínez, Jacqueline Ohmura +12 more

Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.

Journal of Clinical Oncology(2018)10.1200/jco.2018.36.15_suppl.3074

N/A

0.208DataRank · unranked

1 citations

Livnat Jerby-Arnon, Asaf Rotem, Parin Shah, David Liu, Gao Zhang +13 more

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

JCO Precision Oncology(2024)10.1200/po.23.00454

N/A

0.104DataRank · unranked

1 citations

Zihe Song, Helena A. Yu, Lecia V. Sequist, Christine M. Lovly, Edith P. Mitchell +17 more

Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance.

Journal of Clinical Oncology(2018)10.1200/jco.2018.36.15_suppl.9581

N/A

0.104DataRank · unranked

1 citations

Gao Zhang, Alvin Shi, Benjamin Izar, Alexander Heyde, Gyulnara G. Kasumova +14 more

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2188

Top 78%

0.104DataRank

Top 78%1 citations

Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guoren Yang, Jiadi Wen +80 more

Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019

Open Forum Infectious Diseases(2021)10.1093/ofid/ofab153

N/A

0DataRank · unranked

23 citations

James P. Flynn, Alexandra Rosenthal, Hannah Jordan, Yijia Li, Rida Chishti +95 more

The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma

Journal of Investigative Dermatology(2021)10.1016/j.jid.2020.12.035

N/A

0DataRank · unranked

14 citations

Michael F. Shaughnessy, Anpuchchelvi Rajadurai, Michael Taylor, Raj Kumar, Zhenyu Ji +4 more

Rejection of benign melanocytic nevi by nevus-resident CD4 + T cells

Science Advances(2021)10.1126/sciadv.abg4498

N/A

0DataRank · unranked

14 citations

Scarlett Se Yun Cheon, Seokjin Ham, Heehwa G. Son, Jonathan L. Messerschmidt, Donald P. Lawrence +7 more

Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma

Journal of Investigative Dermatology(2021)10.1016/j.jid.2021.07.188

N/A

0DataRank · unranked

5 citations

Zhenyu Ji, Duc Minh Pham, Antoine Simoneau, Raj Kumar, Keith T. Flaherty +3 more

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3087

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Marjorie G. Zauderer, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray +13 more

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.07.03.450733

N/A

0DataRank · unranked

7 citations

Moshe Sade-Feldman, Jaegil Kim, Chip Stewart, Anna Gonye, Arvind Ravi +34 more

Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.342

N/A

0DataRank · unranked

0 citations

Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert Guy Uzzo +5 more

Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth

Nature Metabolism(2022)10.1038/s42255-022-00676-9

N/A

0DataRank · unranked

165 citations

Da Teng, Lifeng Yang, Xincheng Xu, Jiajia Chen, Teng‐Jia Jiang +14 more

HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors

Nature Communications(2022)10.1038/s41467-022-31713-6

N/A

0DataRank · unranked

84 citations

Bin Wu, Ting Li, Lynn A. Beer, Gaurav Sharma, Mingyue Li +23 more

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial

npj Precision Oncology(2022)10.1038/s41698-022-00256-w

N/A

0DataRank · unranked

43 citations

Zihan Wei, Ranee Mehra, Alice T. Shaw, Christopher H. Lieu, Patrick M. Forde +24 more

STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming

Nature Communications(2022)10.1038/s41467-022-29541-9

N/A

0DataRank · unranked

45 citations

Lei Gu, Yeguang Hu, Xiaoyang Zhang, Man Li, Jiajia Chen +20 more

Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V

European Journal of Cancer(2022)10.1016/s0959-8049(22)01026-7

N/A

0DataRank · unranked

3 citations

Zeyuan Song, A. Poklepovic, Eric A. Collisson, Edith P. Mitchell, James Zweibel +15 more

Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

European Journal of Cancer(2022)10.1016/s0959-8049(22)01023-1

N/A

0DataRank · unranked

1 citations

Zeyuan Song, Scott Gettinger, Edith P. Mitchell, JJ Wright, Jeff Moscow +14 more

Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.02.02.478819

N/A

0DataRank · unranked

5 citations

Marijana Ručević, Emmett Sprecher, Milan Parikh, Jiajia Chen, Dennie T. Frederick +23 more

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors

medRxiv(2022)10.1101/2022.02.17.22271120

N/A

0DataRank · unranked

1 citations

Yifan Wang, Rouhi Fazelzad, Benny Johnson, Caroline A. Nebhan, Ibiayi Dagogo‐Jack +24 more

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3334

N/A

0DataRank · unranked

59 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Phase II Study of Palbociclib (PD-0332991) in CCND1 , 2 , or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2150

N/A

0DataRank · unranked

20 citations

Fangxin Hong, Richard S. Finn, Angela DeMichele, Edith P. Mitchell, James A. Zwiebel +18 more

Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0025

N/A

0DataRank · unranked

13 citations

Signe Caksa, Amelia G. Young, Nicole A. Wilski, Connor A. Ott, Inna Chervoneva +6 more

MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment Sequencing for Minimal Residual Disease Detection in Cohort Studies

Clinical Chemistry(2023)10.1093/clinchem/hvad203

N/A

0DataRank · unranked

11 citations

Justin Rhoades, Ruolin Liu, Kan Xiong, Sainetra Sridhar, Andjela Crnjac +7 more

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3108

N/A

0DataRank · unranked

3 citations

Zihan Wei, David S. Hong, Edith P. Mitchell, James A. Zwiebel, Elad Sharon +15 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

(2023)10.1158/1078-0432.c.6529614

N/A

0DataRank · unranked

0 citations

Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur +16 more

Data from Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

(2023)10.1158/1535-7163.c.6532010

N/A

0DataRank · unranked

0 citations

Mercedes Lioni, Maurizia Dalla Palma, Min Xiao, Brijal Desai, Suzanne Egyházi +9 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib

(2023)10.1158/1078-0432.c.6517846.v1

N/A

0DataRank · unranked

0 citations

Christopher R. Zito, Sandra J. Lee, Katherine L. Nathanson, Robert L. Camp, David L. Rimm +3 more

Data from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation

(2023)10.1158/1078-0432.c.6527784.v1

N/A

0DataRank · unranked

0 citations

Jenny Y. Xue, Dennie T. Frederick, Yi Cao, Eva Lin, Catherine Wilson +8 more

Data from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

(2023)10.1158/1078-0432.c.6529614.v1

N/A

0DataRank · unranked

0 citations

Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur +16 more

Data from Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

(2023)10.1158/1535-7163.c.6532010.v1

N/A

0DataRank · unranked

0 citations

Mercedes Lioni, Maurizia Dalla Palma, Min Xiao, Brijal Desai, Suzanne Egyházi +9 more

Data from A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

(2023)10.1158/1078-0432.c.6531102.v1

N/A

0DataRank · unranked

0 citations

Shiyou Wei, Milan R. Savani, Xiang Lin, Kuang Du, Ilgen Mender +33 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100.v1

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib

(2023)10.1158/1078-0432.c.6517846

N/A

0DataRank · unranked

0 citations

Christopher R. Zito, Sandra J. Lee, Katherine L. Nathanson, Robert L. Camp, David L. Rimm +3 more

Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2023)10.1158/2326-6066.22537789

N/A

0DataRank · unranked

0 citations

Donald P. Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou, Tetsuro Sasada +18 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v2

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135

N/A

0DataRank · unranked

36 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

Improving Collection and Analysis of Overall Survival Data

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0919

N/A

0DataRank · unranked

17 citations

Nicole Gormley, Ruixiao Lu, Anup Amatya, George D. Demetri, Keith T. Flaherty +12 more

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0036

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Mark A. Dickson, Angela DeMichele, Richard Piekarz, Robert J. Gray +15 more

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V

JCO Precision Oncology(2024)10.1200/po-24-00514

N/A

0DataRank · unranked

0 citations

Zihe Song, Andrew Poklepovic, Eric A. Collisson, James A. Zwiebel, Robert J. Gray +14 more

Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3531

N/A

0DataRank · unranked

3 citations

Filip Jankú, Ying Yuan, Leylah Drusbosky, Alice P. Chen, Xiaofeng Zheng +15 more

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

Annals of Oncology(2024)10.1016/j.annonc.2024.12.011

N/A

0DataRank · unranked

34 citations

Daniel DiToro, Francesco Facchinetti, E Martin, P. Peng, Islam Baiev +50 more

Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy

(2025)10.1101/2025.10.31.25338685

N/A

0DataRank · unranked

0 citations

Dennie T. Frederick, Alvin Shi, Ana B. Larque, Benchun Miao, Tatyana Sharova +16 more

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Nature Communications(2020)10.1038/s41467-020-19057-5

N/A

0DataRank · unranked

981 citations

James Regan, Kendyll Coxen, Heather Corry, Colline Wong, Alexandra Rosenthal +95 more

Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0329

N/A

0DataRank · unranked

153 citations

Vito W. Rebecca, Aaron R. Goldman, Mitchell E. Fane, Stephen M. Douglass, Reeti Behera +17 more

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djz245

N/A

0DataRank · unranked

231 citations

Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton +35 more

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3443

N/A

0DataRank · unranked

90 citations

Fengmin Zhao, Marcus Smith Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright +15 more

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-2773

N/A

0DataRank · unranked

45 citations

Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur +16 more

SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0291

N/A

0DataRank · unranked

20 citations

Bertrand Fabre, Yongmei Feng, Ali Khateb, Patrick Turko, Julia M. Martínez Gómez +19 more

SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality

Research Square(2020)10.21203/rs.3.rs-43878/v1

N/A

0DataRank · unranked

51 citations

James Regan, Kendyll Coxen, Heather Corry, Colline Wong, Alexandra Rosenthal +25 more

SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality

medRxiv(2020)10.1101/2020.07.15.20131789

N/A

0DataRank · unranked

93 citations

James Regan, Kendyll Coxen, Heather Corry, Colline Wong, Alexandra Rosenthal +25 more

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3506

N/A

0DataRank · unranked

5 citations

Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, L. Austin Doyle +15 more

Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3116

N/A

0DataRank · unranked

0 citations

Neal P. Smith, Moshe Sade-Feldman, Dennie T. Frederick, Russell W. Jenkins, Justine V. Cohen +13 more

Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program (NCORP; EAQ152) COMET trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2008

N/A

0DataRank · unranked

0 citations

Ju‐Whei Lee, Jill B. Gaieski, Shuli Li, Ilana F. Gareen, Keith T. Flaherty +15 more

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

UNC Libraries(2020)10.17615/a8zp-dq08

Top 100%

0DataRank

Top 100%0 citations

Andrew E. Aplin, Yiling Lu, Sébastien Jeay, Carol L. Shields, Michal Barzily-Rokni +49 more

HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma

UNC Libraries(2020)10.17615/paab-v969

N/A

0DataRank · unranked

0 citations

Roger A. Greenberg, C. Elisa Oquendo, M. Celeste Simon, Richard Letrero, Katherine L. Nathanson +7 more

The State of Melanoma: Emergent Challenges and Opportunities

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4092

N/A

0DataRank · unranked

108 citations

Clara Curiel‐Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre‐Ghiso +31 more

Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses

Science Translational Medicine(2021)10.1126/scitranslmed.abd8636

N/A

0DataRank · unranked

97 citations

Masayoshi Kawakubo, Vikram R. Juneja, Mack Y. Su, Tal Hadad Erlich, Martin W. LaFleur +32 more

Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0025

N/A

0DataRank · unranked

46 citations

Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert G. Uzzo +5 more

Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma

Nature Communications(2021)10.1038/s41467-021-26299-4

N/A

0DataRank · unranked

51 citations

Shiyou Wei, Zhi Wei, Dennie T. Frederick, Benchun Miao, Tabea Moll +10 more

Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study

The Oncologist(2021)10.1002/onco.13795

N/A

0DataRank · unranked

43 citations

Douglas B. Johnson, Ryan J. Sullivan, R. Amaria, Keith T. Flaherty, Jeffrey A. Sosman +2 more

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0850

N/A

0DataRank · unranked

32 citations

James H. Doroshow, Susan Galbraith, Antoni Ribas, Paul G. Kluetz, Richard Pazdur +2 more

A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0374

N/A

0DataRank · unranked

30 citations

Shiyou Wei, Milan R. Savani, Xiang Lin, Kuang Du, Ilgen Mender +33 more

Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance

Cancer Research(2021)10.1158/0008-5472.can-20-1496

N/A

0DataRank · unranked

25 citations

Vito W. Rebecca, Andrew V. Kossenkov, Thomas Connelly, Qin Liu, Alexis Gutierrez +43 more

Keith T. Flaherty

Indexed papers

Top data-sharing exemplar

Papers